Agilent to Manufacture siRNA for Intradigm Rx | GenomeWeb
NEW YORK (GenomeWeb News) — Agilent Technologies will manufacture the small-interfering RNA component of an RNAi therapeutic being developed by Intradigm, the firms said last week.
Agilent will supply the siRNA material for use in Intradigm’s preclinical oncology candidate, ICS-283. According to the firms, ICS-283 is the only RNAi therapeutic in development against a clinically validated oncology target, in this case vascular endothelial growth factor.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.